WITH one in seven women living with endometriosis, clinicians now have an alternative and specific treatment option to consider for their patients.
Gedeon Richter Australia announced yesterday the Australian Register of Therapeutic Goods (ARTG) listing of Ryeqo 40/1/0.5 (relugolix, estradiol, norethisterone acetate) in adult women of reproductive age for the symptomatic treatment of endometriosis, with a history of previous medical or surgical treatment for the disease.
Learn more about Ryeqo, a single, once-daily tablet, HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Feb 24
